Apeloa Pharmaceutical's (SHE:000739) unit, Zhejiang Progen Pharmaceutical, received the drug registration certificate for cefdinir capsules from China's National Medical Products Administration, according to a Shenzhen bourse filing on Friday.
The drug is used to treat infections caused by cefdinir-sensitive strains of various bacteria.
The pharmaceutical company's shares rose over 1% during the midday trade.